Angiology最新文献_第8页

Comment on: Performance of Risk Scores in Predicting Right Ventricular Failure After LVAD Implantation. 评价：风险评分在预测左室辅助装置植入后右心室衰竭中的作用。

IF 2.7 3区医学

Angiology Pub Date : 2026-09-16 DOI: 10.1177/00033197261489646

Ismaila Ajayi Yusuf, Olurotimi J Badero

引用次数: 0

Letter: Novel Mechanistic Perspectives on SGLT2 Inhibitor Benefits After Acute Myocardial Infarction: NLRP3 Inflammasome Modulation and Autophagy-Mitochondrial Quality Control. 信函：急性心肌梗死后SGLT2抑制剂获益的新机制视角：NLRP3炎性体调节和自噬-线粒体质量控制。

IF 2.7 3区医学

Angiology Pub Date : 2026-09-15 DOI: 10.1177/00033197261489652

Yuqing Sun

引用次数: 0

Letter: Interpreting Nonsignificant PCI Outcomes Without On-Site Surgical Backup. 信：在没有现场手术支持的情况下解释非显著PCI结果。

IF 2.7 3区医学

Angiology Pub Date : 2026-09-12 DOI: 10.1177/00033197261489650

Liu Boyu, Chen Binbin

引用次数: 0

Exploring the Potential Role of SLC25A25-AS1 in Acute Coronary Syndrome. 探讨SLC25A25-AS1在急性冠脉综合征中的潜在作用。

IF 2.7 3区医学

Angiology Pub Date : 2026-09-10 DOI: 10.1177/00033197261489649

Yan Zhang, Jingxian Bai

引用次数: 0

Liver Fat Content and Carotid Pulse Wave Velocity: Defining the Vascular Phenotype. 肝脏脂肪含量和颈动脉脉搏波速度：定义血管表型。

IF 2.7 3区医学

Angiology Pub Date : 2026-09-07 DOI: 10.1177/00033197261486305

Xu Lingyun, Xia Weijie

引用次数: 0

Letter: Interpreting the Prognostic Value of the Uric Acid-to-Albumin Ratio in Acute Pulmonary Embolism. 信：解释急性肺栓塞中尿酸与白蛋白比值的预后价值。

IF 2.7 3区医学

Angiology Pub Date : 2026-09-03 DOI: 10.1177/00033197261486336

Liu Boyu, Chen Binbin

引用次数: 0

Letter: Triglycerides-Glucose Index as a Novel Biomarker of Prognosis in Patients Coronary Heart Disease. 甘油三酯-葡萄糖指数作为冠心病患者预后的一种新的生物标志物。

IF 2.7 3区医学

Angiology Pub Date : 2026-09-01 Epub Date: 2026-01-11 DOI: 10.1177/00033197251415218

Hai-Ling Hu, Fei Li

引用次数: 0

A Systematic Review of Intracardiac Embolization of Central Venous Catheter Fragment-Unraveling Pandora's Box. 中心静脉导管碎片心内栓塞的系统回顾——打开潘多拉的盒子。

IF 2.7 3区医学

Angiology Pub Date : 2026-09-01 Epub Date: 2025-11-05 DOI: 10.1177/00033197251384358

Chaoneng Wu, Shayne Joseph, Rakesh Devireddy, Maxim Zlatopolsky, Omar Qaqish, Yunguo C Gong, Sonela Blaceri, Chadi Saad, William E Harder, Sujata Kambhatla, Ashok Kondur

{"title":"A Systematic Review of Intracardiac Embolization of Central Venous Catheter Fragment-Unraveling Pandora's Box.","authors":"Chaoneng Wu, Shayne Joseph, Rakesh Devireddy, Maxim Zlatopolsky, Omar Qaqish, Yunguo C Gong, Sonela Blaceri, Chadi Saad, William E Harder, Sujata Kambhatla, Ashok Kondur","doi":"10.1177/00033197251384358","DOIUrl":"10.1177/00033197251384358","url":null,"abstract":"A systematic review was conducted to investigate the relationship between the duration of intracardiac central venous catheter (CVC) fragment embolization and its manifestations and interventions. We searched the MEDLINE, Embase, Google Scholar, and Scopus databases over a 4-decade period. The collected data included CVC type, duration from implantation to identification of embolization, symptomatology, embolization sites, interventional approaches, and outcomes. Out of 295 cases, 62.4% of embolizations occurred within the first year, with 13% occurring in the pulmonary artery only. Based on clinical manifestations, the duration in CVC malfunctioning group was the shortest (median 37.5 weeks, interquartile Range [IQR] 13-53.2, P < 0.05 vs asymptomatic and symptomatic groups). In terms of interventions, the percutaneous retrieval group had the shortest duration (median 34.8 weeks, P < .05 vs surgical retrieval or non-retrieval groups). A logistic regression analysis indicated that a shorter duration predicted a higher success rate of percutaneous retrieval (odds ratio = 1.007, 95% CI = 1.004-1.010, P < .0001), while being symptomatic forecasted a higher probability of non-percutaneous retrieval (odds ratio = 0.195, 95% CI = 0.063-0.610, P = 0.0448). We suggest that earlier identification of fragmented catheters, especially in malfunctioning CVC, increases the success rate of percutaneous retrieval.","PeriodicalId":8264,"journal":{"name":"Angiology","volume":" ","pages":"974-980"},"PeriodicalIF":2.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145450187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letter: Reply to "Carotid Disease and Cerebrovascular Risk Following TAVI: Insights and Remaining Questions". 回复“TAVI后颈动脉疾病和脑血管风险：见解和遗留问题”。

IF 2.7 3区医学

Angiology Pub Date : 2026-09-01 Epub Date: 2025-12-04 DOI: 10.1177/00033197251405926

Marko Bulic, Nadjib Schahab

引用次数: 0

Autologous Cell Therapy for Chronic Limb Threatening Ischemia: Towards Personalized Medicine. 自体细胞治疗慢性肢体缺血：迈向个体化治疗。

IF 2.7 3区医学

Angiology Pub Date : 2026-09-01 Epub Date: 2025-10-17 DOI: 10.1177/00033197251376093

Eugenio Caradonna, Francesco Setacci, Jessica Lanza, Fulvio Ferrara, Carlo Setacci, Massimo Danese, Gaetano Lanza

{"title":"Autologous Cell Therapy for Chronic Limb Threatening Ischemia: Towards Personalized Medicine.","authors":"Eugenio Caradonna, Francesco Setacci, Jessica Lanza, Fulvio Ferrara, Carlo Setacci, Massimo Danese, Gaetano Lanza","doi":"10.1177/00033197251376093","DOIUrl":"10.1177/00033197251376093","url":null,"abstract":"Peripheral Artery Disease (PAD) with Chronic Limb Threatening Ischemia (CLTI) is a severe condition at risk of amputation, and often conventional surgical and endovascular procedures and/or medical therapy are insufficient. The present review considers current knowledge regarding autologous cell therapy and regenerative medicine for PAD with CLTI. We evaluated cell-based therapies in the recent literature, that are pivotal in treating vascular disorders by promoting angiogenesis, vascular restoration, and tissue regeneration; furthermore, we provided an overview of the relevant main clinical studies. Clinical conditions and risk factors of patients correlate with the performance of autologous cell-based therapies and the probability of success. Nevertheless, the current evidence indicates that these therapies are promising, necessitating further research. Autologous cell therapy and regenerative medicine can offer additional support for treating PAD with CLTI. These advanced techniques are becoming more tailored and substantial for their application in clinical practice. Personalized Medicine represents a contemporary paradigm that calls for consideration of individual patient's clinical conditions, risk factors, and biomarkers.","PeriodicalId":8264,"journal":{"name":"Angiology","volume":" ","pages":"961-973"},"PeriodicalIF":2.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13379602/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145312135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0